Comparison · NCT01694108-b7cada6c
BCG-vaccine vs Control Children: Specific IgE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BCG-vaccine vs Control Children: Specific IgE. Trial comparisons, record NCT01694108-b7cada6c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01694108-b7cada6c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.074 | 0.0573 | 0.0951 | wilson | |
| Risk in group 2 | 0.0797 | 0.061 | 0.104 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00572 | -0.0348 | 0.0225 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.928 | 0.643 | 1.34 | log | |
| Odds ratio, group 1 over group 2 | 0.923 | 0.619 | 1.37 | log | |
| Number needed to treat, for one fewer participant with the outcome on BCG-vaccine than on Control Children | 175 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BCG-vaccine | SSI strain 1331 standard dose | 55 | 743 | OG000 |
| Group 2 | Control Children | No intervention | 50 | 627 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Specific IgE
- Description
- Number of participants with specific IgE (Phadiatop Infant) above the clinical cut-of level of 0.35.
- Time frame
- 13 months of age
- Population
- This analysis includes children who participated with blood samples for this sub-study regarding specific IgE.
Source ClinicalTrials.gov
Trial
- Title
- Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.
- NCT number
- NCT01694108
- Phases
- PHASE4
- Conditions
- Prospective, Single-blind, Clinical, Trial, Intervention
- Interventions
- BCG-vaccine (SSI)
- Lead sponsor
- Lone Graff Stensballe
- Results first posted
- 2016-01-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01694108?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01694108-b7cada6c